Citi opened a “90-day positive catalyst watch” on shares of Zimmer Biomet (ZBH) while keeping a Neutral rating on the name with a $120 price target Zimmer has shown incremental improvements in defending its knee and hip market share, with both segments’ share becoming more stable year-over-year compared to the start of the year, the analyst tells investors in a research note. The firm says that given a “reasonable setup” into 2025 and an attractive valuation compared to peers, “some consistency is needed to get sentiment on track.”
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZBH:
- Zimmer announces FDA clearance of Persona SoluTion Porous Plasma Spray Femur
- Zimmer Biomet assumed with an Equal Weight at Morgan Stanley
- Zimmer Biomet receives FDA approval for Oxford Cementless Partial Knee
- Trump Trade: President-elect seeks to kill Biden fuel-efficiency rules
- Zimmer Biomet announces CE Mark certification for knee system